Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma

British Journal of Haematology

Volumn 120, Issue 6, 2003, Pages 970-977

  Chau, Ian ^a,b   Harries, Mark ^a,b   Cunningham, David ^a,b   Hill, Mark ^c   Ross, Paul J ^a,b   Archer, Caroline D ^a,b   Norman, Andrew R ^a,b   Wotherspoon, Andrew ^a,b   Koh, Dow Mu ^a,b   Gill, Kairen ^a,b   Uzzell, Maggie ^a,b   Prior, Yvonne ^a,b   Catovsky, Daniel ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c Kent Oncology Centre   (United Kingdom)

Author keywords

Cisplatin; Gemcitabine; Lymphoma; Primary progressive; Relapse

Indexed keywords

CISPLATIN; GEMCITABINE; METHYLPREDNISOLONE;

ADOLESCENT; ADULT; ALOPECIA; ANEMIA; ARTICLE; B LYMPHOCYTE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENTEROPATHY; HISTOLOGY; HODGKIN DISEASE; HUMAN; INFECTION; LEUKOPENIA; MANTLE CELL LYMPHOMA; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROBABILITY; RELAPSE; SALVAGE THERAPY; STOMATITIS; T LYMPHOCYTE; THROMBOCYTOPENIA; TINNITUS; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; LYMPHOMA; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE-CELL, DIFFUSE; LYMPHOMA, MANTLE-CELL; LYMPHOMA, T-CELL; MALE; METHYLPREDNISOLONE; MIDDLE AGED; RECURRENCE; SURVIVAL RATE;

EID: 0037353902     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04226.x     Document Type: Article

References (50)

1. Abratt, R.P., Sandler, A., Crino, L., Steward, W.P., Shepherd, F.A., Green, M.R., Nguyen, B. & Peters, G.J. (1998) Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery. Seminars in Oncology, 25, 35-43.
2. Aisenberg, A.C. (1999) Problems in Hodgkin's disease management. Blood, 93, 761-779.
3. Bass, A.J., Gockerman, J.P., Hammett, E., DeCastro, C.M., Adams, D.J., Rosner, G.L., Payne, N., Davis, P., Foster, T., Moore, J.O. & Rizzieri, D.A. (2002) Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma. Journal of Clinical Oncology, 20, 2995-3000.
4. Bernell, P. & Ohm, L. (1998) Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphoma. British Journal of Haernatology, 101, 203-204.
5. Blay, J., Gomez, F., Sebban, C., Bachelot, T., Biron, P., Guglielmi, C., Hagenbeek, A., Somers, R., Chauvin, F. & Philip, T. (1998) The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood, 92, 3562-3568.
6. Bokemeyer, C., Berger, C.C., Hartmann, J.T., Kollmannsberger, C., Schmoll, H.J., Kuczyk, M.A. & Kanz, L. (1998) Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. British Journal of Cancer, 77, 1355-1362.
7. Braakhuis, B.J., Ruiz, V.H.V., Welters, M.J. & Peters, G.J. (1995) Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. European Journal of Cancer, 31A, 2335-2340.
8. Canellos, G.P. (1998) Treatment of relapsed Hodgkin's disease: strategies and prognostic factors. Annals of Oncology, 9, s91-s96.
9. Canellos, G.P., Anderson, J.R., Propert, K.J., Nissen, N., Cooper, M.R., Henderson, E.S., Green, M.R., Gottlieb, A. & Peterson, B.A. (1992) Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. New England Journal of Medicine, 327, 1478-1484.
10. Cardenal, F., Lopez-Cabrerizo, M.P., Anion, A., Alberola, V., Massuti, B., Carrato, A., Barneto, I., Lomas, M., Garcia, M., Lianes, P., Montalar, J., Vadell, C., Gonzalez-Larriba, J.L., Nguyen, B., Artal, A. & Rosell, R. (1999) Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer, Journal of Clinical Oncology, 17, 12-18.
11. Chau, I., Webb, A., Cunningham, D., Hill, M., Rao, S., Ageli, S., Norman, A., Gill, K., Howard, A. & Catovsky, D. (2001) An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. British Journal of Haematology, 115, 786-792.
12. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.
13. Corazzelli, F., Capobianco, G., Frigeri, F., Russo, F., Marcacci, G. & Pinto, A. (2002) Combination of gemcitabine and oxaliplatin (GEMOX) in refractory and relapsed NHL. Annals of Oncology, 13, 159a.
14. Crino, L., Scagliotti, G.V., Ricci, S., De Marinis, F., Rinaldi, M., Gridelli, C., Ceribelli, A., Bianco, R., Marangolo, M., Di Costanzo, F., Sassi, M., Barni, S., Ravaioli, A., Adamo, V., Portalone, L., Cruciani, G., Masotti, A., Ferrara, G., Gozzelino, F. & Tonato, M. (1999) Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. Journal of Clinical Oncology, 17, 3522-3530.
15. Crump, M., Baetz, T., Belch, A., Couban, S., Meyer, R., Imrie, K., Paul, N., Shepherd, L. & Iglesias, J. (2002) Gemcitabine, dexamethasone, cisplatin (GDP) chemotherapy for relapsed or refractory non-Hodgkin's lymphoma and Hodgkin's disease. Annals of Oncology, 13, 158a.
16. Dumontet, C., Morschhauser, F., Solal-Celigny, P., Bouafia, F., Bourgeois, E., Thieblemont, C., Leleu, X., Hequet, O., Salles, G. & Coiffier, B. (2001) Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. British Journal of Haematology, 113, 772-778.
17. Emmanoullides, C., Colovos, C., Pinter-Brown, L., Territo, M.C. & Rosen, P.J. (2002) A gemcitabine, cisplatin and dexamethazone combination in patients with multiple relapsed Hodgkin's and non-Hodgkin's lymphoma. Annals of Oncology, 13, 159a.
18. Fossa, A., Santoro, A., Hiddemalm, W., Truemper, L., Niederle, N., Buksmaui, S., Bonadonna, G., Seeber, S. & Nowrousian, M.R. (1999) Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology, 17, 3786-3792.
19. Gehan, E.A. (1961) The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent, Journal of Chronic Diseases, 13, 346-353.
20. Germann, N., Brienza, S., Rotarski, M., Emile, J.F., Di Palma, M., Musset, M., Reynes, M., Soulie, P., Cvitkovic, E. & Misset, J.L. (1999) Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients. Annals of Oncology, 10, 351-354.
21. Grunewald, R., Kantarjian, H., Keating, M.J., Abbruzzese, J., Tarassoff, P. & Plunkett, W. (1990) Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Research, 50, 6823-6826.
22. Grunewald, R., Du Kantarjian, H.M., Faucher, K., Tarassoff, P. & Plunkett, W. (1992) Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. Journal of Clinical Oncology, 10, 406-413.
23. Hickish, T., Roldan, A., Cunningham, D., Mansi, J., Ashley, S., Nicolson, V., Gore, M.E., Catovsky, D. & Smith, I.E. (1993) EPIC: an effective low toxicity regimen for relapsing lymphoma. British Journal of Cancer, 68, 599-604.
24. Hitt, R., Castellano, D., Hidalgo, M., Garcia-Carbonero, R., Pena, M., Brandariz, A., Millan, J.M., Alvarez Vincent, J.J. & Cortes-Funes, H. (1998) Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck. Annals of Oncology, 9, 1347-1349.
25. Jaffe, E.S., Harris, N.L., Stein, H. & Vardiman, J.W. (2001) World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues IARC Press, Lyon.
26. Josting, A., Franklin, J., May, M., Koch, P., Beykirch, M.K., Heinz, J., Rudolph, C., Dtehl, V. & Engert, A. (2002) New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. Journal of Clinical Oncology, 20, 221-230.
27. Kaplan, E.L. & Meier, P. (1958) Non parametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
28. Kroep, J.R., Peters, G.J., van Moorsel, C.J., Catik, A., Vermorken, J.B., Pinedo, H.M. & van Groeningen, C.J. (1999) Gemcitabine-cisplatin: a schedule finding study. Annals of Oncology, 10, 1503-1510.
29. Linch, D.C., Winfield, D., Goldstone, A.H., Moir, D., Hancock, B., McMillan, A., Chopra, R., Milligan, D. & Hudson, G.V. (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet, 341, 1051-1054.
30. von der Maase, H., Hansen, S.W., Roberts, J.T., Dogliotti, L., Oliver, T., Moore, M.J., Bodrogi, I., Albers, P., Knuth, A., Lippert, C.M., Kerbrat, P., Sanchez, R.P., Wersall, P., Cleall, S.P., Roychowdhury, D.F., Tomlin, I., Visseren-Grul, C.M. & Conte, P.F. (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. Journal of Clinical Oncology, 18, 3068-3077.
31. Machover, D., Delmas-Marsalet, B., Misra, S.C., Gumus, Y., Goldschmidt, E., Schilf, A., Frenoy, N., Emile, J.F., Debuire, B., Guettier, C., Farrokhi, P., Boulefdaoui, B., Norol, F., Parquet, N., Ulusakarya, A. & Jasmin, C. (2001) Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma. Annals of Oncology, 12, 1439-1443.
32. Mink, S.A. & Armitage, J.O. (2001) High-dose therapy in lymphomas: a review of the current status of allogeneic and autologous stem cell transplantation in Hodgkin's disease and non-Hodgkin's lymphoma. Oncologist, 6, 247-256.
33. van Moorsel, C.J., Pinedo, H.M., Veerman, G., Bergman, A.M., Kuiper, C.M., Vermorken, J.B., van der Vijgh, W.J. & Peters, G.J. (1999a) Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. British Journal of Cancer, 80, 981-990.
34. van Moorsel, C.J., Kroep, J.R., Pinedo, H.M., Veerman, G., Voorn, D.A., Postmus, P.E., Vermorken, J.B., van Groeningen, C.J., van der Vijgh, W.J. & Peters, G.J. (1999b) Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. Annals of Oncology, 10, 441-448.
35. van Moorsel, C.J., Pinedo, H.M., Veerman, G., Vermorken, J.B., Postmus, P.E. & Peters, G.J. (1999c) Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice. European Journal of Cancer, 35, 808-814.
36. Nagourney, R.A., Link, J.S., Blitzer, J.B., Forsthoff, C. & Evans, S.S. (2000) Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. Journal of Clinical Oncology, 18, 2245-2249.
37. Peters, G.J., Bergman, A.M., Ruiz van Haperen, V.W., Veerman, G., Kuiper, C.M. & Braakhuis, B.J. (1995) Interaction between cisplatin and gemcitabine in vitro and in vivo. Seminars in Oncology, 22, 72-79.
38. Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van Der, L.H., Bron, D., Sonneveld, P., Gisselbrecht, C., Cahn, J.Y., Harousseau, J.L., Coiffier, B., Biron, P., Mandelli, F. & Chauvin, F. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New England Journal of Medicine, 333, 1540-1545.
39. Sallah, S., Wan, J.Y. & Nguyen, N.P. (2001) Treatment of refractory T-cell malignancies using gemcitabine. British Journal of Haematology, 113, 185-187.
40. Sandler, A.B., Nemunaitis, J., Denham, C., von Pawel, J., Cormier, Y., Gatzemeier, U., Mattson, K., Manegold, C., Palmer, M.C., Gregor, A., Nguyen, B., Niyikiza, C. & Einhorn, L.H. (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. Journal of Clinical Oncology, 18, 122-130.
41. Santoro, A., Bredenfeld, H., Devizzi, L., Tesch, H., Bonfante, V., Viviani, S., Fiedler, F., Parra, H.S., Benoehr, C., Pacini, M., Bonadonna, G. & Diehl, V. (2000) Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. Journal of Clinical Oncology, 18, 2615-2619.
42. Savage, D.G., Rule, S.A., Tighe, M., Garrett, T.J., Oster, M.W., Lee, R.T., Ruiz, J., Heitjan, D., Keohan, M.L., Flamm, M. & Johnson, S.A. (2000) Gemcitabine for relapsed or resistant lymphoma. Annals of Oncology, 11, 595-597.
43. Schiller, J.H., Harrington, D., Belani, C.P., Langer, C., Sandler, A., Krook, J., Zhu, J. & Johnson, D.H. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New England Journal of Medicine, 346, 92-98.
44. Schmitz, N., Pfistner, B., Sextro, M., Sieber, M., Carella, A.M., Haenel, M., Boissevain, F., Zschaber, R., Muller, P., Kirchner, H., Lohri, A., Decker, S., Koch, B., Hasenclever, D., Goldstone, A.H. & Diehl, V. (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet, 359, 2065-2071.
45. Shepherd, F.A., Abratt, R., Crino, L., Green, M., Sandler, A., Steward, W., Iglesias, J. & Anglin, G. (2000) The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer. Lung Cancer, 30, 117-125.
46. Therasse, P., Arbuck, S.G., Eisenhauer, E.A., Wanders, J., Kaplan, R.S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A.T., Christian, M.C. & Gwyther, S.G. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer. National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of National Cancer Institute, 92, 205-216.
47. Von Hoff, D.D., Schilsky, R., Reichert, C.M., Reddick, R.L., Rozencweig, M., Young, R.C. & Muggia, F.M. (1979) Toxic effects of cis-dichlorodiammineplatinum (II) in man. Cancer Treatment Report, 63, 1527-1531.
48. Warkentin, D., Ippoliti, C., Bruton, J., Van Besien, K. & Champlin, R. (1999) Toxicity of single daily dose gentamicin in stem cell transplantation. Bone Marrow Transplantation, 24, 57-61.
49. Zinzani, P.L., Baliva, G., Magagnoli, M., Bendandi, M., Modugno, G., Gherlinzoni, F., Orcioni, G.F., Ascani, S., Simoni, R., Pileri, S.A. & Tura, S. (2000a) Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. Journal of Clinical Oncology, 18, 2603-2606.
50. Zinzani, P.L., Bendandi, M., Stefoni, V., Albertini, P., Gherlinzoni, F., Tani, M., Piccaluga, P.P. & Tura, S. (2000b) Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica, 85, 926-929.